Seaport Therapeutics, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Daphne Zohar
- Full Time Employees
- 58
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 101 Seaport Blvd. Boston MA United States of America 02210-2186
- IPO Date
- May 1, 2026
- CIK
- 0002042347
- Website
- seaporttx.com
- Similar Companies
- Business
- Seaport Therapeutics, Inc. provides clinical-stage neuropsychiatric medicines developed through its Glyph platform, focusing on orally bioavailable agents designed to bypass first-pass metabolism and minimize liver-related side effects; products include SPT-320, a prodrug of agomelatine intended for Generalized Anxiety Disorder, and other Glyph-based candidates targeting antidepressant and anxiolytic indications; operations primarily in the United States with headquarters in Boston, Massachusetts, and a global development focus aimed at addressing high unmet patient needs in mental health. Founded in 2023, the company advances a pipeline of first- and best-in-class therapies under a strategy built on clinically validated mechanisms that overcome prior development limitations; it pursues strategic partnerships, funding rounds, and potential acquisitions to accelerate clinical programs and expand its Glyph-enabled portfolio. Seaport collaborates with venture and growth investors to support its Series A- and B-scale financing activity and to fund ongoing clinical trials and platform optimization; its investor relations and corporate governance activities align with industry best practices to support long-term value creation for stakeholders. The company’s core business activities include research and development of novel neuropsychiatric medicines, translational science using the Glyph platform, regulatory strategy and interactions, and collaborations with biopharmaceutical partners to advance clinical candidates through Phase 1 and beyond; its market positioning centers on delivering first-in-class or best-in-class therapies with improved oral bioavailability and reduced hepatic risk profiles for patients with schizophrenia-related neuropsychiatric conditions and anxiety disorders. SPTX, the company’s common stock, trades on major U.S. exchanges, reflecting market-driven financing and strategic milestones achieved through ongoing capital market activities and clinical progress updates.
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
Seaport Therapeutics raises about $255 million in upsized IPO
Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering
Drug developer Seaport Therapeutics targets $912 million valuation in US IPO